AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2025 and provided 2026 financial guidance. Preliminary, unaudited revenue for fourth quarter 2025 is expected to be $140.5 million, reflecting growth of approximately 13% over the fourth quar.

Business Wire • Jan 12, 2026

AtriCure, Inc. (ATRC) Soars to 52-Week High, Time to Cash Out?

AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • Jan 9, 2026

Has AtriCure (ATRC) Outpaced Other Medical Stocks This Year?

Here is how AtriCure (ATRC) and Ensign Group (ENSG) have performed compared to their sector so far this year.

Zacks Investment Research • Dec 24, 2025

AtriCure (ATRC) Is Up 6.32% in One Week: What You Should Know

Does AtriCure (ATRC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Dec 19, 2025

AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming J.P. Morgan 44th Annual Healthcare Conference. AtriCure's management is scheduled to present on Wednesday, January 14, 2026, at 10:30 a.m. Pacific Standard Time. Interested parties may access a live aud.

Business Wire • Dec 17, 2025

ATRC Treats First Patients Using Novel Dual-Energy PFA-RFA Platform

AtriCure's first patients treated with its dual-energy PFA-RFA platform mark a key step as it moves toward a clinical trial next year.

Zacks Investment Research • Dec 12, 2025

AtriCure Announces the First Patients Treated with Novel Dual Energy Platform

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced successful first-in-human treatments using its novel dual energy platform that integrates Pulsed Field Ablation (PFA) with Advanced Radiofrequency Ablation (Advanced RFA). The procedures were performed by Dr. Adrian Pick in collaboration with the site Princi.

Business Wire • Dec 11, 2025

Are Medical Stocks Lagging AtriCure (ATRC) This Year?

Here is how AtriCure (ATRC) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Zacks Investment Research • Dec 8, 2025

Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?

AtriCure Board of Directors member Sven Wehrwein sold 10,000 shares in the company on Nov. 24 and 25, 2025. The transaction was valued at nearly $377,000.

The Motley Fool • Nov 29, 2025

Wall Street Analysts Believe AtriCure (ATRC) Could Rally 36.3%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in AtriCure (ATRC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Nov 25, 2025